The Research Center Borstel is a member of the Leibniz-Association (WGL). Currently, the Leibniz Association is a syndication of 87 scientific, legally authorized and economically independent research institutes and service facilities in Germany and accordingly, one of the largest German scientific organizations. All of the Leibniz institutions are actively engaged in thematically defined, future oriented fields of research which are of global interest. The consequent, transparent and strictly external assessment procedure is a singular hallmark of the WGL in comparison to the other university and external university research organizations in Germany.
The Research Center Borstel, the Leibniz Institute of Virology, LIV and the Bernhard-Nocht-Institute (BNI) are mutual founding members of the Leibniz Center Infection (LCI). The three institutes are constituent members of the Leibniz Association and each has, respectively, a clear cut biological infection mission.
The Research Center Borstel is focused on bacteria induced infections of the lung, e.g. tuberculosis. The LIV is mainly working on human viral diseases, whereas the BNI devotes itself to research on tropical diseases, especially parasitic infections. Altogether, approximately 1,000 persons are employed at the three institutes, around 300 of whom are scientists.
The aim of LCI (flyer) is to advance inventive and innovative basic research concerning biological infection in the Hamburg/Schleswig Holstein region. Correlations between science and methodology are to be identified; cooperative research projects initiated and improved possibilities for the evaluation of research results are to be established.
Leibniz Graduate School "Model Systems for Infectious Diseases"
Leibniz Research Alliances
Leibniz institutions form collaborative research alliances which use inter- and transdisciplinary approaches to address current scientific and socially-relevant issues.
The alliances are designed for a period of five to 15 years and are open for collaboration with universities, other non-university research institutions and infrastructure facilities as well as research groups abroad.
The FZB is currently partner in the following networks:
- Pharmaceutical Agent and Biotechnology
- Medical Technology: Diagnosis, Monitoring and Therapy.
The Leibniz research alliance "INFECTIONS in an Urbanizing World - Humans, Animals, Environments" on the control, prevention and control of infectious diseases is coordinated by the FZB and funded by the Leibniz Association under the funding line "Strategic Networking". The interdisciplinary consortium includes 18 Leibniz Institutes from four sections, of which 15 institutes are full members and three institutes are associate members, as well as three external partners.
INFECTIONS builds on the established structures of interdisciplinary research culture and communication of the predecessor consortium INFECTIONS'21 in order to be able to quickly address new challenges posed by infectious diseases across disciplinary boundaries. Strategies for early warning systems and risk assessments, also involving the public, are to be developed that can prevent the rapid spread of pathogens and thus improve the management of infectious outbreaks from a One Health perspective in humans and animals.
DUSTRISK: Health index for dust and associated microbes, 2020-2023
Research Network 'Lung microbiota at the interface between airway epithelia and environment'
Leibniz ScienceCampus Kiel
Leibniz ScienceCampi promote cooperation on an equal footing between Leibniz institutions and universities in the form of thematically-focused, complementary regional partnerships. The objective is to create networks to drive the respective research field and to strengthen the scientific environment for the relevant themes. The networks conduct strategic research, encourage interdisciplinarity in their topics, projects and methods, enhance the visibility of the respective location and hone its research profile.
The Leibniz ScienceCampus „Evolutionary Medicine of the Lung“ (EvoLUNG). EvoLUNG is based on an approved partnership between FZB, Christian-Albrechts-Universität zu Kiel and the Max-Planck-Institute for Evolutionary Biology in Plön. The objectives to be reached are interdisciplinary research to elucidate severe lung diseases by evolution scientific methods followed by the development of new therapies for diseases such as asthma, tuberculosis, mucoviscidosis and COPD.
Leibniz ScienceCampus Hamburg
Leibniz ScienceCampus „Integrative analysis of pathogen-induced compartments“ (InterACt). Partners are the Heinrich-Pette-Institute, the Bernhard-Nocht-Institute, the University of Hamburg, the University Medical Center Eppendorf and the Centre for Structural Systems Biology.